CYCN News and Press, Cyclerion Therapeutics Inc. From 04/25/19

CAMBRIDGE, Mass., April 25, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that it wi...

CAMBRIDGE, Mass., April 09, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that Andre...

Insider buying declined significantly last week with insiders purchasing $27.16 million of stock compared to $79.08 million in the week prior. Selling also declined sharply with insiders selling $747.39 million of stock last week compared to $1.87 billion in the week prior. Sell/Buy Ratio: ...